New AI-driven technology integration marks a first in the U.S., enhancing patient access to specialized care and streamlining complex scheduling…
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…
Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are…
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical…
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and…
CARSON CITY, Nev., June 12, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company…
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare…
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025…
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on…
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and…